Background: Breast cancer remains the most common cancer among women worldwide and a major cause of preventable cancer mortality, particularly in resource-constrained settings where delayed presentation is common. Breast self-examination (BSE) does not replace clinical assessment...
Open access
Research Article10.9734/jamps/2026/v28i10895
Introduction: Estrogen receptor-positive/HER2-negative breast cancer is the most common molecular subtype of breast cancer. Aromatase inhibitors such as letrozole are part of the standard endocrine treatment regimen for postmenopausal patients; however, real-world evidence on pat...
Open access
Research Article10.9734/jamps/2026/v28i8883
Sara S. Abdelrahim, Mohammed H. Alnazeer, Mawahib A. Mustafa, Safa A. Abdalla, Elkhanssa Abdelhameed Ahmed Elhag, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef·Journal of Advances in Medical and Pharmaceutical Sciences·2026
Background: Imatinib mesylate is a tyrosine kinase inhibitor that has transformed the treatment of chronic myeloid leukaemia. However, information on its real-world use among sub-Saharan African populations remains limited. Aims: This study evaluated early haematological response...
Open access
Research Article10.9734/jamps/2026/v28i8879